Zydus Cadila Gets SEC Nod for Clinical Trial of Antibodies Cocktail to Treat Covid-19: Report

Zydus Cadila Gets SEC Nod for Clinical Trial of Antibodies Cocktail to Treat Covid-19: Report Zydus Cadila has SEC permission for Clinical Trial of Antibodies Cocktail for Covid-19 treatment (Image Courtesy: Zydus Cadila)

New Delhi: Zydus Cadila, the only Indian company which claims to have successfully developed neutralising monoclonal antibodies (mAbs)-based cocktail for the treatment of COVID-19, has been given permission to conduct clinical trials by the Subject Expert Committee (SEC) of Central Drugs Standard Control Organisation (CDSCO), according to ANI sources.

Indian company Zydus Cadila which claims to have developed neutralising monoclonal antibodies (mAbs)-based cocktail for the treatment of COVID-19 has been given permission to conduct clinical trials by the Subject Expert Committee (SEC) of Central Drugs Standard Control Organisation (CDSCO), according to ANI sources.

“SEC gives a recommendation for the Phase I and II clinical trials of Zydus Cadila’s biological therapy ZRC-3308, a cocktail of two SARS-CoV-2-neutralising monoclonal antibodies (mAbs) that can emerge as one of the main treatments for mild COVID-19,” the sources said.

ALSO READ: 84-yr-old Mohabbat Singh from Haryana, first in India to get antibody cocktail against Covid-19 mutant

These antibodies are made by cloning unique white blood cells. Domestic pharmaceutical major Zydus Cadila has sought the Drug Controller General of India (DCGI) permission recently to undertake clinical trials. Zydus Cadila on Thursday had said it is seeking permission from Drugs Controller General of India (DCGI) to initiate human clinical trials for monoclonal antibodies cocktail for treatment of COVID-19.

READ ALSO: Zydus Cadila seeks govt nod to conduct human trial of Covid-19 antibody cocktail

Zydus said that its biological therapy ZRC-3308, a cocktail of two SARS-CoV-2-neutralising monoclonal antibodies (mAbs) can emerge as one of the main treatments for mild COVID-19.

Currently, some of the hospitals are administering the cocktail of two fast-acting anti-bodies – Casirivimab and Imdevimab, the batch of the Roche Antibody Cocktail drug arrived in the country on May 24.

The cost of a single antibody cocktail is Rs 59,750. Another antibody cocktail that has received permission is Eli Lilly and Company, India announced that it has received permission for restricted emergency use of its antibody drugs, bamlanivimab 700mg and etesevimab 1400mg, in India for the treatment of patients with mild to moderate coronavirus disease 2019.

(With ANI Inputs)

For the latest News, Breaking News, Top News, like us on Facebook or follow us on Twitter and YouTube